Khan Najat 4

What Happened

• Najat Khan, CEO, President and Director of Recursion Pharmaceuticals (RXRX), was granted two restricted stock unit (RSU) awards on 2026-02-06 totaling 1,703,892 shares (1,673,546 and 30,346) at $0.00 per share.
• In connection with the net settlement of the RSUs, 10,364 shares were withheld by the company to satisfy tax withholding obligations; those withheld shares are reported as disposed at $3.98 each for a total of $41,249. This was an award/grant transaction (not an open-market purchase or sell).

Key Details

• Transaction date: 2026-02-06; Form filed: 2026-02-10 (appears to be filed after the typical two-business-day window).
• Grants: 1,673,546 RSUs (vesting schedule) and 30,346 RSUs (vested immediately). Both reported as acquired at $0.00.
• Tax withholding: 10,364 shares withheld/disposed at $3.98 each, proceeds reported as $41,249. (Code F = tax withholding/net settlement.)
• Shares owned after the transaction: not reported in the provided data.
• Footnotes: F1 = larger RSU vests one‑sixteenth on May 15, 2026 and then quarterly thereafter; F2 = the 30,346 RSU vested immediately; F3 = withheld shares satisfy tax withholding in connection with net settlement.

Context

• The grants are compensation (RSUs); the withholding of shares to cover taxes is a routine administrative step (a cashless/net settlement), not an open‑market sale.
• Grants signal company compensation to the executive rather than a personal buy or sell decision; purchases are typically more informative about insider sentiment.
• The filing date is later than the usual two-business-day reporting window, which may be noteworthy to investors tracking timeliness of insider disclosures.